Aristo Bio-Tech Releases Audited Financial Results for Half Year and Fiscal Year Ended March 31, 2026
Aristo Bio-Tech And Lifescience Limited announced key operational updates following its Board Meeting held on Saturday, May 30, 2026. The company approved and recorded the Audited Standalone Financial Results for the half year and the full financial year ended on March 31, 2026.The Board meeting confirmed the approval of the Audited Standalone Financial Statements for the financial year ended March 31, 2025, in accordance with the Companies Act, 2013.
Financial Performance Summary
The audited results show significant figures for both the half-year and the full fiscal year. The standalone financial results are presented below, with amounts in Rupees Lakh.Profit and Loss Account Summary
| Particulars | 6 Months Ended 31-03-26 | Year Ended 31-03-26 | 6 Months Ended 31-03-25 | Year Ended 31-03-25 |
|---|---|---|---|---|
| Total Revenue | 10,763.44 | 36,417.37 | 25,653.93 | 31,854.63 |
| Profit Before Tax | 415.32 | 969.76 | 554.44 | 546.69 |
| Profit from Ordinary Activities | 301.31 | 718.26 | 416.96 | 411.47 |
| Earnings Per Equity Share (Basic) | 4.43 | 10.55 | 6.12 | 6.04 |
Balance Sheet Overview
The company's financial position was assessed as of March 31, 2026, compared to the previous year.
| Particulars | As on 31-03-26 (Rs. In lakh) | As on 31-03-25 (Rs. In lakh) |
|---|---|---|
| Share Capital | 680.78 | 680.78 |
| Reserves and Surplus | 3,770.62 | 3,052.35 |
| Total Equity and Liabilities | 15,521.59 | 14,062.39 |
| Current Liabilities (Total) | 6,490.20 | 7,456.59 |
| Total Assets | 15,521.59 | 14,062.39 |
Cash Flow Statement Highlights
The cash flow from operating activities saw a notable improvement for the fiscal year.
| Activity | Amount for the period ending 31-03-26 (Rs. In lakh) | Amount for the period ending 31-03-25 (Rs. In lakh) |
|---|---|---|
| Cash flow from operating activities | 844.44 | 1,001.66 |
| Net Cash flow from Investing Activities | -297.00 | -514.68 |
| Net Cash flow from Financing Activities | -396.34 | -439.14 |
| Net Increase in Cash & Cash Equivalent | 151.10 | 47.84 |
Dividend Recommendation
The Board recommended a final dividend of Rs. 0.60 (Rupees Sixty Paisa only) per Equity share. This dividend, which represents 6% of the face value of Rs. 10 per equity share, is subject to the approval of the company members at the ensuing Annual General Meeting. The payment of the final dividend will be dispatched after the Annual General Meeting.Audit Report
The Standalone Financial Results for the half year and year ended March 31, 2026, were reviewed and recommended by the Audit Committee and approved by the Board of Directors. The audit report issued by Prakash Chandra Jain & Co. expressed an unmodified opinion on the standalone audited financial results for the period.Narendra Singh Barhat, Chairman and Managing Director, also confirmed the approval of the standalone audited financial results and the statement of assets and liabilities.
ARISTO Stock Price Movement
On Friday, Aristo Bio-Tech And Lifescience Limited shares settled flat, closing at ₹109.8 after recording no change for the day. The stock saw 800 shares traded, marking a steady, non-directional close in the sector.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.